$3.74
arrow_drop_up1.08%Key Stats | |
---|---|
Open | $3.70 |
Prev. Close | $3.70 |
EPS | -1.85 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $178.26M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 3.64 | 3.79 |
52 Week Range | 1.33 | 11.76 |
Ratios | |
---|---|
EPS | -1.85 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
Wall Street Breakfast: The Week Ahead
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
Assessing Shattuck Labs: Insights From 6 Financial Analysts
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)